-
11:41:46 PM

EIGR Stock News

08/14/23 4:05 PM
Nasdaq : EIGR
earnings
Eiger BioPharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
Resources prioritized to advance avexitide in hyperinsulinemic hypoglycemia indications Active discussions underway with potential partners to advance late-stage virology programs Reduction in workforce executed to align with focus on avexitide; extends cash runway into Q4 2024 David Apelian, MD, PhD, MBA, appointed CEO. PALO ALTO, Calif., Aug. 14, 2023/...
RHEA-AI
neutral
03/16/23 4:28 PM
Nasdaq : EIGR
earnings
Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus and other serious diseases, today reported financial results for fourth quarter and full year 2022 and provided a business update. "In December, we announced that both our lonafarnib-based...
RHEA-AI
positive
02/08/23 5:00 PM
Nasdaq : EIGR
clinical trialcovid-19
New England Journal of Medicine Publishes Positive Phase 3 TOGETHER Results with Peginterferon Lambda in COVID-19
Eiger BioPharmaceuticals Inc., a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus and other serious diseases, today announced the publication of data from the investigator-sponsored Phase 3 TOGETHER study in patients with COVID-19 in the New England Journal of Medicine. The...
RHEA-AI
neutral